Biotechnology
ASCO 2023 | Ascentage Pharma to Present Results from 4 Studies Highlighting Extended Therapeutic Potential of Lead Drug Candidates
SUZHOU, China, and ROCKVILLE, MD, April 27, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clinical studies of the c...
2023-04-27 17:44
2452
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...
2023-04-26 22:15
3993
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of ul...
2023-04-26 21:16
3647
J INTS BIO, AACR 2023 - Presentation of preclinical study results of 'JIN-A04', an oral target therapy for HER2 exon insertion mutation NSCLC
SEOUL, South Korea, April 25, 2023 /PRNewswire/ -- J INTS BIO announced the poster presentation of its novel, orally administered TKI 'JIN-A04' targeting NSCLC with HER2 exon 20 insertion mutation at the annual meeting of the American Association of Cancer Research 2023, which was held inOrlando,...
2023-04-26 09:53
2136
BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States
* The Official State visit by the President of the Republic of Korea marks the 70th anniversary of the U.S.-ROK alliance, which is advancing peace, stability, and prosperity for the two countries, for theAsia-Pacific region, and globally * President Yoon Suk Yeol and First Lady Kim Keon Hee o...
2023-04-25 20:00
2081
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
* Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute * Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to T...
2023-04-25 13:46
2467
Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company's Quality Management System
SUZHOU, China and ROCKVILLE, Md., April 24, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it recently received a zero-deficiency repor...
2023-04-25 08:42
2693
A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology
SHANGHAI, April 24, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. ("OBiO" or "the Company"), a leading gene and cell therapy CDMO inChina, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in theChina (Shang...
2023-04-24 22:36
4161
WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022
Revenue Up 5.8% Year-Over-Year to RMB8,964 Million Net Profit Attributable to Owners of the Company Up 32.0% Year-Over-Year to RMB2,168 Million Diluted Earnings per Share (EPS) Up 35.8% Year-Over-Year to RMB0.72 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 14.1% Year-Over-...
2023-04-24 18:03
3511
Samsung Biologics Reports First Quarter 2023 Financial Results
* Recorded Q1'23 consolidated revenue of KRW 720.9 billion. * Recorded Q1'23 consolidated operating profit of KRW 191.7 billion. * Expected to maintain a strong growth trajectory with the full utilization of existing and newly expanded capacities. INCHEON, South Korea, April 24, 2023 /PRNews...
2023-04-24 14:51
3146
Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207, a 4th generation EGFR TKI
* The company has been notified by the FDA that the Phase 1/2 clinical trial may proceed * The latest preclinical data explored the antitumor efficacy and the intracranial activity of BBT-207 SEONGNAM, South Korea and CAMBRIDGE, Mass., April 23, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ...
2023-04-24 10:00
2480
ITRI Took Home Three Edison Awards(TM) in 2023
HSINCHU, April 21, 2023 /PRNewswire/ -- The highly-anticipated 2023 Edison
Awards™
2023-04-21 19:27
3875
ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer
SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr.Oliver Kong as Chief Medical Officer (CMO). Dr. Kong will be fully in charge of global clinical development and international collaboration of company pipelines, and participate in overall c...
2023-04-21 09:06
2884
CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer
SHANGHAI, April 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CT041, an autologous CAR T-cell product candidate against the p...
2023-04-20 20:50
3138
CBC GROUP AND MUBADALA CO-LEAD US$315 MILLION FUNDRAISING ROUND FOR HASTEN BIOPHARMA
Proceeds raised will be used to fund future acquisitions, and fuel business development of innovative pipeline assets SINGAPORE, April 20, 2023 /PRNewswire/ -- CBC Group ("CBC"), Asia's largest healthcare-dedicated investment firm headquartered inSingapore, and Hasten Biopharmaceutic Company Lim...
2023-04-20 13:00
3316
Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
ROCKVILLE, Md. and SUZHOU, China, April 19, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...
2023-04-20 08:00
2544
Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses
CAMBRIDGE, Mass., April 18, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge technology innovation and provider of integrated solutions from "Idea to IND" (I to ITM), announced today it has entered into a collaboration agreement w...
2023-04-19 08:45
2753
AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting
SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time,
ImmVira presented preclinical study results of CAR-T enabler oHSV product
MVR-7011 through poster publication at the American Association for Cancer
Research ("AACR") annual meeting.
2023-04-19 08:29
2278
Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting
* New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate * Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to initiate the first-in-human study of BBT-207 this year SEONGNAM, South Korea and CAMBRIDG...
2023-04-19 07:00
2618
South Korean Biotech, ToolGen Leads the Development of Numerous Cutting-Edge Genome Editing Techniques
SEOUL, South Korea, April 18, 2023 /PRNewswire/ -- Until now, most of the major
breakthroughs in the CRISPR field have been led by US academics. Not anymore;
Toolgen, aSouth Korea-based biotech company, has reported three breakthrough
techniques in top-tier scientific journals.
2023-04-18 21:00
2795
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 314 media titles]
2026-06-08 10:16
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 303 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 296 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 294 media titles]
2026-06-05 15:00Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 283 media titles]
2026-06-08 09:00
Most Read
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
2026-06-05 19:37
8472
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
8061
Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval
2026-06-05 22:00
7546
CERAVE CELEBRATES OVER 100 AWARD-WINNING CONTENT CREATORS FROM 22 COUNTRIES FOR THE FIRST EVER GLOBAL CERAWARDS
2026-06-05 20:58
7400
Tuniu Announces Unaudited First Quarter 2026 Financial Results
2026-06-05 18:00
7323